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Tsg101 and the Vacuolar Protein Sorting Pathway
Are Essential for HIV-1 Budding
(Go¨ttlinger et al., 1991; Huang et al., 1995), and it has
therefore been termed a “late domain” (Wills and Cra-
ven, 1991). Virus assembly appears to initiate normally in
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other budding particles) is not severed, resulting in ab-David G. Myszka,2 and Wesley I. Sundquist1,4
normal or severely attenuated virus release.1Department of Biochemistry
The recruitment of cellular machinery to facilitate virus2 Center for Biomolecular Interaction Analysis
budding seems to be a general phenomenon, and dis-University of Utah School of Medicine
tinct late domains have been identified in the structuralSalt Lake City, Utah 84132
proteins of many enveloped viruses (Vogt, 2000). Two3 Myriad Genetics
well-characterized late domains are the “PY” motif (con-Salt Lake City, Utah 84108
sensus sequence: PPXY; X  any amino acid) found in
membrane-associated proteins from filo-, orbi-, rhabdo-
and oncoretroviruses (Craven et al., 1999; Harty et al.,Summary
1999, 2000; Jayakar et al., 2000), and the “YL” motif
(YXXL) found in the Gag protein of equine infectiousLike other enveloped viruses, HIV-1 uses cellular ma-
anemia virus (EIAV) (Puffer et al., 1997, 1998). The variouschinery to bud from infected cells. We now show that
late domains can still function when moved to differentTsg101 protein, which functions in vacuolar protein
positions within retroviral Gag proteins, supporting thesorting (Vps), is required for HIV-1 budding. The UEV
idea that they are docking sites for cellular factors ratherdomain of Tsg101 binds to an essential tetrapeptide
than structural elements (Parent et al., 1995; Yuan et al.,(PTAP) motif within the p6 domain of the structural
2000). Moreover, the different late domains can functionGag protein and also to ubiquitin. Depletion of cellular
interchangeably, and multiple late domains are oftenTsg101 by small interfering RNA arrests HIV-1 budding
found in close proximity within viral coat proteins, sug-at a late stage, and budding is rescued by reintroduc-
gesting that they may act synergistically (Parent et al.,tion of Tsg101. Dominant negative mutant Vps4 pro-
1995; Strack et al., 2000; Yuan et al., 2000).teins that inhibit vacuolar protein sorting also arrest
Ubiquitin (Ub) also plays an essential, albeit poorlyHIV-1 and MLV budding. These observations suggest
understood, role in retroviral budding (Patnaik et al.,that retroviruses bud by appropriating cellular machin-
2000; Schubert et al., 2000b; Strack et al., 2000; Vogt,ery normally used in the Vps pathway to form multi-
2000). For example, retrovirus budding can be blockedvesicular bodies.
at a late stage by depleting cellular pools of free ubiquitin
with proteasome inhibitors. It is not yet certain, however,Introduction
whether the functionally relevant substrate for ubiquiti-
nation is Gag itself or a cellular factor. HIV-1 p6 andHIV-1 assembly is driven by the viral Gag protein, which
other retroviral Gag proteins are monoubiquitinated atis actively trafficked to the plasma membrane where it
low levels (Ott et al., 2000), and there is a general correla-associates into enveloped, spherical particles that bud
tion between Gag ubiquitination and virus release (Schu-from the cell (reviewed in Freed, 1998). During viral as-
bert et al., 2000b; Strack et al., 2000). Moreover, thesembly, Gag is processed by the viral protease at a
block imposed by proteasome inhibitors can be at least
series of sites to produce four new structural proteins
partially alleviated by covalently fusing Ub to the C-ter-
that perform essential functions in the mature, infectious
minal end of Rous sarcoma virus (RSV) Gag (Patnaik et
virion (denoted MA, CA, NC, and p6; Figure 1A). Proteo- al., 2000). However, virus release and replication are not
lytic processing is not required for particle production, affected by mutation of the two HIV-1 p6 lysine residues
however, as HIV-1 Gag can assemble and bud in the (Lys-27 and Lys-33) that are the major sites for Gag
absence of any other viral proteins. ubiquitination (Ott et al., 2000). The functional role of Gag
The budding of an enveloped virus can be viewed as ubiquitination therefore remains uncertain. In principle,
a fission event in which the continuous cell membrane is Gag ubiquitination could facilitate budding either by tar-
broken and resealed to create discrete viral and cellular geting defective Gag molecules for proteolytic degrada-
membranes. Like other enveloped viruses, HIV-1 does tion and thereby preventing them from interfering with
not encode its own membrane fission machinery, and viral budding (Schubert et al., 2000a), or by creating
presumably therefore must recruit and reprogram cellu- docking sites for cellular factors that actively participate
lar proteins to assist in the budding process. A potential in viral budding.
docking site for such a cellular factor(s) has been To understand how HIV-1 and other enveloped viruses
mapped to a conserved P(T/S)AP motif located in the bud, it is essential to define the participating cellular
p6 domain of HIV-1 Gag. Point mutations within this factors. We now report that human tumor susceptibility
“PTAP” motif arrest viral release at a very late stage gene 101 (Tsg101) is required for the release of infec-
tious HIV-1 and suggest that the protein facilitates bud-
ding by linking the p6 late domain to vacuolar protein4 Correspondence: wes@biochem.utah.edu
5 These authors contributed equally to this work. sorting machinery.
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Figure 1. Human Tsg101 Binds HIV-1 p6
(A) HIV-1 Gag domain structure and dissociation constants for pure Tsg101 UEV protein binding to immobilized HIV-1 GST-p6 and GST-p6-Ub
proteins. The standard deviation in the dissociation constant for the full-length, wild-type p6 protein was derived from 16 independent
measurements; estimated errors in the final significant digits of the other dissociation constants (parentheses) were derived from statistical
fits of individual isotherms to 1:1 binding models.
(B) SDS-PAGE analysis showing induced expression in E. coli and fully purified Tsg101 UEV.
(C) Surface plasmon resonance biosensor analysis of the p6/Tsg 101 interaction. Tsg101 UEV was injected in triplicate at concentrations of
0, 0.9, 0.27, 0.82, 2.5, 7.4, 22, 67, and 200 M over GST-p6 captured on an anti-GST surface. Data were double referenced to correct for bulk
refractive index changes and any nonspecific binding (Myszka, 1999).
(D) Representative binding isotherms for Tsg101 UEV interacting with a series of different protein surfaces.
(E) Epitope mapping of the Tsg101 UEV binding site on HIV-1 p6. The graph shows the changes in free energy of Tsg101 UEV binding (G)
caused by single alanine substitutions in HIV-1 p6 residues 4–13 (dark bars) or by the P7L, T8I, A9R, and P10L mutations (light bars). Positive
values indicate that the mutation reduces binding affinity, and error bars show estimated standard deviations in single binding isotherms.
Broken lines above the P10L mutant denote a lack of detectable Tsg101 UEV binding (see also Figure 1D).
Results half of Tsg101 (residues 1–207, data not shown). Com-
parative sequence analyses have suggested that this
region of Tsg101 contains a domain that belongs to theHuman Tsg101 Binds Specifically to the PTAP
Motif of HIV-1 p6 ubiquitin enzyme 2 variant (UEV) protein family (Koonin
and Abagyan, 1997; Ponting et al., 1997; VanDemark etCarter and coworkers have recently reported using a
yeast two-hybrid screen to identify Tsg101 as a p6 bind- al., 2001). UEV proteins are homologous to the E2 class
of ubiquitin conjugating enzymes, but lack the active siteing protein (VerPlank et al., 2001). We independently
used a similar strategy to screen for proteins that could cysteine residue required to make a transient thioester
bond during ubiquitin transfer, and are presumably notbind to the PTAP late domain within HIV-1 p6 and ob-
tained similar results. Briefly, HIV-1NYU/BR5 p6 was used enzymatically active. A construct spanning Tsg101 resi-
dues 1–145 was used to characterize the interactionas bait to screen a human spleen cDNA prey library for
potential binding partners. Genes encoding nearly full- between HIV-1NL4-3 p6 and the Tsg101 UEV domain in
vitro. Recombinant Tsg101 UEV was expressed in E.length Tsg101 were isolated twice, and were the only
genes detected and confirmed in these screens. In sub- coli, purified to homogeneity, and tested for binding
to immobilized GST-p6 fusion proteins using a surfacesequent experiments, we showed that full-length Tsg-
101 bound wild-type p6 in directed two-hybrid liquid plasmon resonance biosensor (Figure 1). Tsg101 UEV
exhibited concentration-dependent p6 binding, andculture assays, resulting in high levels of -galactosi-
dase activity (300-fold over background; not shown). equilibrium responses fit a simple 1:1 binding model
with an equilibrium dissociation constant (Kd20C) of 27 Three different p6 point mutants (P7L, A9R, and P10L)
were used to test whether the Tsg101 binding interaction 5M. As summarized in Figure 1A, a series of constructs
spanning p6 residues 1–13, 1–27, 1–33, and 1–52 (full-required the PTAP motif within HIV-1 p6, and all three
reduced -galactosidase activity to background levels. length p6) all bound Tsg101 UEV with similar affinities.
Thus, the primary Tsg101 binding site is located withinEach of these point mutations also arrests HIV-1 bud-
ding at a late stage (Huang et al., 1995). Hence, Tsg101 the first 13 residues of p6.
Site-directed mutagenesis of p6 was then used towas judged an attractive candidate for the cellular factor
that binds the PTAP late domain of HIV-1 p6 and facili- map the Tsg101 binding site more precisely. Residues
4–13 within full-length p6 were substituted individuallytates viral budding.
Directed yeast two-hybrid experiments were further with alanine (Figure 1E, dark bars) or with residues
known to block virus release (light bars). Mutations in theused to map the primary p6 binding site to the N-terminal
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four central PTAP residues significantly reduced Tsg101
binding (2 kcal/mol loss of binding free energy). Muta-
tions at three flanking sites (E6A, P11A, and E13A) mod-
erately reduced the binding affinity (0.3–0.5 kcal/mol),
indicating that these residues also contributed to
Tsg101 UEV binding. Alanine substitutions at three other
sites (R4A, P5A, and E12A) had no significant effect on
Tsg101 UEV binding. These experiments demonstrate
that the Tsg101 UEV domain binds directly and specifi-
cally to HIV-1 p6 and that the p6 PTAP motif is the
energetically dominant binding epitope. Our data are in
excellent agreement with the study of VerPlank et al.,
who also showed that Tsg101 binding was PTAP-spe-
cific (VerPlank et al., 2001).
Ubiquitin Modification of HIV-1 p6 Enhances
Tsg101 Binding
We reasoned that ubiquitination of HIV-1 p6 might en-
hance Tsg101 UEV binding, because other UEV proteins
can bind ubiquitin (VanDemark et al., 2001) and because
ubiquitin is required for HIV-1 budding (Schubert et al.,
2000b; Strack et al., 2000). The enzymes that conjugate
Ub onto HIV-1 Gag are not yet known, so models for
p6-Ub conjugates were created by fusing the Ub protein
in frame to the C termini of full-length p6, p633, and
Figure 2. Tsg101 Is Required for Release of HIV-1 from 293T Cellsp627 constructs (Figure 1A). Analogous approaches have
(A) Anti-Tsg101 Western blot showing depletion of Tsg101 proteinbeen employed by others to rescue Ub-dependent de-
from 293T cells by siRNA and restoration of Tsg101 protein usingfects in endocytosis (Shih et al., 2000) and RSV budding
siRNA-resistant expression constructs. Cells were cotransfected(Patnaik et al., 2000). In all three p6-Ub constructs, the
twice (2 ml cultures, 6-well plates) with plasmid DNA and with 50
presence of ubiquitin increased the affinity of Tsg101 nM siRNA or siRNAINV at 24 hr intervals (except mock, lane 1, which
UEV binding approximately 10-fold (ave. Kd  2.3 M; received no RNA or DNA). The first siRNA/siRNAINV cotransfection
Figures 1A and 1D). Tsg101 UEV even bound weakly to was with 2 g or 4 g of a Tsg-FLAG (siRNA-sensitive) or Tsg*-
FLAG (siRNA-resistant) expression construct. The second siRNA/Ub alone (Figure 1D, est. Kd  510  35 M). These
siRNAINV cotransfection was with 0.5g HIV-1 R9 DNA. In each case,experiments demonstrate that Tsg101 UEV, though
total transfected DNA was normalized to 4.5 g with pIRES2-EGFP.lacking enzymatic activity, has retained Ub binding ac-
Cytoplasms and supernatants were analyzed 48 hr after the first
tivity and can bind cooperatively to ubiquitin and to the transfection.
HIV-1 p6 late domain. We envision that Tsg101 could (B) Anti-FLAG Western blot showing that the Tsg101*-FLAG con-
bind ubiquitinated Gag molecules even more tightly in struct is resistant to siRNA. Samples were prepared in (A).
(C) Anti-MA and anti-CA Western blot showing that depletion ofvivo if the UEV domain senses the native Ub isopeptide
Tsg101 inhibits virus release. From cells transfected in (A), viralgeometry or if oligomerization of full-length Tsg101 in-
particles were pelleted from the supernatant of the transfected cells.creases its avidity for the assembling Gag lattice.
Virus release in untreated cells was similar to that in the siRNAINV-
treated cells (not shown).
Tsg101 Is Required for Efficient Release of HIV-1 (D) Anti-MA and anti-CA Western blot showing that cytoplasmic
levels of HIV-1 Gag, CA, and MA proteins are not affected by Tsg101from 293T Cells
depletion. Note that levels of MA and CA in cellular membraneIt was important to develop systems to test the require-
fractions increased significantly when virus release was blockedment for cellular Tsg101 in HIV-1 budding. Others have
(not shown).
shown that the HIV-1 p6 late domain can mediate virus (E) Viral replication assays showing that release of infectious virus
release from human embryonic kidney 293T cells (Yuan is inhibited when Tsg101 is depleted and rescued when Tsg101
et al., 2000), and we confirmed that a series of mutations is restored. Titers of infectious HIV-1 particles released into the
supernatant (shown) were quantitated in single cycle MAGIC assays.in the p6 PTAP sequence that block HIV-1 release and
replication in other cell lines also blocked release of
infectious HIV-1 particles in 293T cells (data not shown).
We next tested whether we could deplete Tsg101 from Tsg101 protein could only be detected in highly overex-
posed Western blots, whereas levels of control proteins293T cells using small interfering RNAs (siRNA) (Elbashir
et al., 2001). The system was optimized until it became were unaffected (not shown). Nuclear and membrane
fractions were also depleted of Tsg101 (not shown). Apossible to deplete endogenous Tsg101 to nearly unde-
tectable levels (Figure 2A, lanes 2, 8, and 10). Briefly, heterologous control RNA duplex of inverted sequence
(denoted siRNAINV) did not affect cellular Tsg101 levels,293T cells were transfected twice at 24 hr intervals with a
small interfering RNA duplex homologous to nucleotides demonstrating the specificity of siRNA. Although others
have reported that altering Tsg101 levels can affect cell413–433 of the Tsg101 coding sequence (denoted
siRNA). Tsg101 levels were analyzed after an additional proliferation (Zhong et al., 1998), we observed only a
very slight growth reduction in Tsg101-depleted cells24 hr by Western blotting of cytoplasmic extracts from
the bulk culture. Under these conditions, traces of over the 72 hr time course.
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Tsg101 protein was reintroduced into Tsg101-depleted
cells by cotransfecting a plasmid encoding FLAG-
tagged Tsg101 protein with 7 silent mutations at the
siRNA target site that rendered the gene resistant to
RNA interference (denoted Tsg*-FLAG). As shown in
Figures 2A and 2B, this “resistant” Tsg*-FLAG protein
was not depleted by siRNA (lanes 4 and 6). In contrast,
endogenous Tsg101 and exogenous Tsg-FLAG ex-
pressed from wt genes were always efficiently depleted
by siRNA treatment.
To test whether Tsg101 was required for HIV-1 bud-
ding, Tsg101-depleted cells were cotransfected with a
proviral HIV-1 R9 expression construct during the sec-
ond siRNA transfection. Depletion of Tsg101 very signifi-
cantly reduced the release of virion-associated MA and
CA proteins as analyzed in Western blots, and also re-
duced viral infectivity in single cycle MAGIC infectivity
assays (Figures 2C and 2E, lanes 2, 8, and 10). Viral
titers were reduced 10- to 50-fold in multiple repetitions
of this experiment. Both virus release and infectivity
were restored to normal levels when the Tsg*-FLAG pro-
tein was reintroduced (lanes 4 and 6), formally demon-
strating that Tsg101 is required for the release of infec-
tious HIV-1 from 293T cells. Reductions in virus release
in the Tsg101-depleted cells did not reflect general de-
fects in HIV-1 Gag protein synthesis, stability, or pro-
cessing (Figure 2D). However, Tsg101 depletion repro-
ducibly increased accumulation of the CA-SP1 Gag Figure 3. Depletion of Tsg101 Does Not Affect MLV Release or In-
processing intermediate in the cytoplasm, consistent fectivity
with a defect in the final stages of particle assembly (A) Depletion of Tsg101 does not significantly inhibit MLV release
(Gottlinger et al., 1991). from 293T cells.
Upper panel: Anti-Tsg101 and anti-14-3-3 Western blot showingWe also tested the effect of Tsg101 depletion on the
specific depletion of Tsg101 from 293T cells by siRNA. Depletionrelease of murine leukemia virus (MLV), which uses the
experiments were performed as described in Figure 2A, except thatalternative “PY” late domain pathway (Yuan et al., 1999).
the second siRNA cotransfection was with 1.5 g pCLeco and 0.25
As expected, mutating the MLV Gag p12 PPPY motif (to
g pCLlacZ MLV vector DNA. Levels of 14-3-3 protein are shown
AAAA) blocked particle release and infectivity (Figure as loading controls, and a pCLeco vector expressing PPPY mutant
3). However, depletion of Tsg101 had only a minor effect, Gag is shown as a positive control for arrested budding (lane 7).
Middle panel: Anti-MLV CA Western blot showing that virus releaseif any, on MLV release and infectivity. These experiments
is not significantly reduced by Tsg101 depletion.demonstrate that Tsg101-depleted 293T cells can still
Lower panel: Anti-CA Western blot showing cytoplasmic levels ofsupport replication of retroviruses other than HIV-1, pro-
MLV Gag.
vided they are not released via the PTAP-dependent (B) Depletion of Tsg101 does not significantly inhibit MLV infectivity.
pathway. Infectious MLV particles released into the supernatant were quanti-
tated in single cycle infectivity assays and normalized to the appro-
priate controls. In repetitions of these experiments, siRNA treatmentA Functional Vps Pathway Is Required for HIV-1
reduced particle release and infectivity slightly (up to 2-fold) relativeRelease from 293T Cells
to the siRNAINV control.Tsg101 functions in the vacuolar protein sorting (Vps)
pathway, in which membrane-associated proteins are
sorted through a series of endosomal compartments GFP-Vps4 fusion proteins induces formation of enlarged
endosomes (called “class E” compartments in yeast)for eventual degradation in the lysosome (Lemmon and
Traub, 2000). To test whether Tsg101 might link viral that are defective in the sorting and recycling of endocy-
tosed substrates (Bishop and Woodman, 2000). Thebudding to the cellular Vps pathway, we examined the
effects of other “functional knockouts” of the Tsg101/ Vps4 mutants also prevent normal Tsg101 trafficking
because the protein is trapped on the surface of theseVps pathway on HIV-1 budding. Although Tsg101 is pre-
dominantly cytosolic at steady state (Xie et al., 1998; aberrant endosomes (Bishop and Woodman, 2001).
To test the requirement for Tsg101/Vps function inZhong et al., 1998), the protein appears to cycle dynami-
cally through the endosomal network. Another protein HIV-1 particle release, vectors expressing ATPase-
defective GFP-Vps4 proteins were cotransfected to-in the Vps pathway, Vps4, functions in Tsg101 cycling
and endosomal trafficking (Babst et al., 1998; Bishop gether with the proviral HIV-1 R9 expression vector.
Two different dominant negative mutations were used:and Woodman, 2000, 2001). Vps4 is an ATPase of the
AAA protein family that appears to utilize the energy K173Q, which blocks ATP binding (Vps4K173Q), and
E228Q, which blocks ATP hydrolysis (Vps4E228Q). Proteinderived from ATP hydrolysis to disassemble endosome-
associated Vps complexes and thereby allow multiple levels and viral infectivity were again analyzed by West-
ern blotting and in MAGIC assays. As shown in Figuresrounds of sorting. Overexpressing ATPase-defective
Tsg101 and HIV-1 Budding
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Figure 4. Mutant Vps4 Proteins Dominantly
Inhibit HIV-1 Release and Infectivity
(A) Mutant Vps4 proteins dominantly inhibit
HIV-1 release. 293T cells were transfected
with 0.5 g R9 plasmid encoding wt HIV-1
(lanes 2 and 4–10) or a p6 PTAP mutant
HIV-1 (lane 3). Cells were cotransfected with
pEGFP (1 g, lane 2), GFP-Vps4 wt (1 g,
lane 4), GFP-Vps4K173Q (0.25, 0.5, or 1g; lanes
5–7), or GFP-Vps4E228Q (0.25, 0.5, or 1g; lanes
8–10). Total DNA was normalized to 1.5 g
with pEGFP. Pelleted virus (above) and cyto-
plasmic extracts (labeled Cell, below) were
harvested after 24 hr, and levels of expressed
CA, MA, and GFP-Vps4 proteins analyzed by
Western blotting.
(B) Mutant Vps4 proteins dominantly inhibit
HIV-1 infectivity. Levels of infectious HIV-1
particles released into the supernatant were
quantitated using single cycle MAGIC assays.
Samples were from (A).
(C) Mutant Vps4 proteins dominantly inhibit
release of Gag-GFP. 293T cells were trans-
fected with 1 g vector expressing wt Gag-
GFP (lanes 2 and 4–6) or a p6 PTAP mutant Gag-GFP (lane 3). Samples were cotransfected with 1 g vector expressing GFP only (lane 2),
wt GFP-Vps4 (lane 4), GFP-Vps4K173Q (lane 5), or GFP-Vps4E228Q (lane 6). Pelleted virus-like particles (above) and cytoplasmic extracts (below)
were harvested after 24 hr, and Gag and GFP-Vps4 expression were analyzed by Western blotting with anti-MA, anti-CA (top two panels),
and anti-GFP antibodies (bottom panel).
(D) PTAP mutation and dominant negative Vps4 proteins inhibit release of infectious HIV-1 from MT4 T cells. Cells were transfected (24-well
plates) with 1 g HIV-1 R9 DNA and 1 g Vps4 DNA or 1 g control DNA (pEGFP). Levels of infectious HIV-1 particles released into the
supernatant were quantitated using single cycle MAGIC assays.
4A and 4B, coexpression of the mutant GFP-Vps4 pro- cruits components of the Tsg101/Vps pathway to assist
in budding.teins inhibited particle production in a dose-dependent
fashion, with release of infectious particles reduced
more than 1000-fold at the highest levels of Vps4E228Q A Functional Vps Pathway Is Required for Release
of Infectious HIV-1 from Human T Cell Linestested. Cotransfection with the wild-type GFP-Vps4
construct reduced particle production and infectivity We also tested whether an intact PTAP motif and a
functional Vps pathway were required for release of in-only slightly (2- to 3-fold). This reduction was repro-
ducible, however, and may reflect stoichiometric imbal- fectious HIV-1 particles from T cells, which are HIV-1
hosts in vivo. Although the transfection efficiencies ofances in the Vps pathway arising from Vps4 overexpres-
sion. Expression levels for all of the GFP-Vps4 proteins T cell lines are low, viral titers produced from MT4 cells
72 hr posttransfection were sufficiently high to quanti-paralleled the levels of transfected DNA (as detected by
anti-GFP Western, Figure 4A, bottom), and none of the tate using the MAGIC assay. Mutation of HIV-1 p6 PTAP
reduced viral titers 300-fold (Figure 4D) and blockedVps4 proteins altered Gag protein synthesis, stability,
or cell viability significantly (Figure 4A, middle). Other spreading infections in MT4 cultures (growth curves not
shown). Thus, HIV-1 also requires p6 PTAP to replicate incontrols for this experiment included: (1) mock transfec-
tions (lane 1), (2) cotransfection of R9 with a vector this nonadherent T cell line. Inhibition of the Vps pathway
by overexpression of the dominant negative Vps4E228Qexpressing GFP only (no effect on budding; lane 2), and
(3) transfection of an R9 vector encoding a PTAP to LIRL mutant also severely reduced infectious HIV-1 titers
(200-fold), whereas overexpression of the wt Vps4 pro-mutant HIV-1 provirus (arrested budding; lane 3).
As the Vps4 mutants interfered with endosomal traf- tein had only modest effects (3-fold reduction). Similar
results were obtained in the CEMss T cell line (data notficking, we considered the possibility that particle re-
lease might have been inhibited by altered trafficking, shown). Thus, we conclude that HIV-1 requires both a
PTAP motif and a functional Vps pathway to replicateactivation, or assembly of viral proteins other than Gag
(e.g., protease (PR), envelope (Env), or viral protein U). in multiple cell types, including T cells.
This was not the case, however, because the mutant
GFP-Vps4 proteins also blocked release of viral con- A Functional Vps Pathway Is Required for Release
of Infectious MLV from 293T Cellsstructs missing PR or Env (data not shown) and even
blocked release of Gag-GFP alone (Figure 4C, lanes 5 The effects of mutant GFP-Vps4 protein overexpression
on MLV particle release and infectivity in 293T cells wereand 6). As expected, Gag-GFP was released efficiently
in the absence of the dominant negative Vps constructs, also tested (Figure 5). In this case, virion-associated CA
release was blocked, with a concomitant increase inbut was blocked by mutation of the Gag p6 PTAP se-
quence (lane 3). These experiments demonstrate that cytoplasmic levels of the unprocessed Gag protein
(lanes 5 and 6). Similarly, infectivity was dramaticallythe Vps4-induced block to HIV-1 release does not re-
quire any other viral proteins, consistent with the idea reduced (800-fold for Vps4E228Q). Thus, the block to viral
release imposed by the Vps4 mutants is more generalthat the p6 domain of the assembling Gag particle re-
Cell
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pathway (for both HIV-1 and MLV) participate in this final
stage of viral particle release.
Discussion
Our experiments demonstrate a requirement for Tsg101
in HIV-1 budding. In summary, Tsg101 UEV binds specif-
ically to the PTAP motif within p6 (VerPlank et al. (2001)
and this work), and there is an excellent correlation be-
tween mutations that inhibit Tsg101 binding and those
that inhibit virus release (Huang et al., 1995). Depleting
Tsg101 or inhibiting endosomal trafficking also arrests
HIV-1 release at a late stage, indicating that Tsg101 and
the Vps pathway perform essential functions in viral
budding. Thus, these proteins represent potentially at-
tractive new targets for therapeutic intervention.
The studies described herein also demonstrate the
power of using the siRNA method developed by Tuschl
and coworkers to test the functional requirement for a
protein in a biological process (Elbashir et al., 2001). We
have extended the utility of this technique by showingFigure 5. Mutant Vps4 Proteins Dominantly Inhibit MLV Release and
that exogenous, siRNA-resistant protein expressionInfectivity
constructs can be used in functional rescue experi-(A) 293T cells were cotransfected with 1.5 g pCLeco and 0.25 g
ments. In principle, this same approach can also bepCLlacZ MLV vectors encoding wt (lanes 2 and 4–6) or PPPY
mutant MLV Gag proteins (lane 3). Cotransfections were with 1 g used to test the functional phenotypes of site-directed
of the following vectors: pEGFP expressing GFP only (lanes 2, 3), mutant proteins in mammalian cells. More generally,
wt GFP-Vps4 (lane 4), GFP-Vps4K173Q (lane 5), or GFP-Vps4E228Q (lane these siRNA techniques are complementary to yeast
6). Pelleted virus (upper panel) and cytoplasmic extracts (lower pan- two-hybrid and surface plasmon resonance experi-
els) were harvested after 24 hr, and levels of expressed MLV CA,
ments, and can be combined to reveal potential newGag, and GFP-Vps4 proteins were analyzed by Western blotting
binding partners for a target protein, characterize theirwith anti-MLV CA and anti-GFP antibodies as indictated.
interactions, and analyze their biological functions.(B) Mutant Vps4 proteins dominantly inhibit MLV replication. Sam-
ples were prepared as described in Figure 5A and MLV vector titers
were quantitated as described in Experimental Procedures. Protein Binding Motifs in Tsg101 UEV
We have shown that Tsg101 UEV is a multifunctional
domain that can simultaneously bind both ubiquitin andthan that imposed by depleting Tsg101, which appears
the p6 PTAP motif, suggesting that Tsg101 may detect,
to be HIV-specific. These observations indicate that late
or possibly participate in, the Ub transfer event required
endosomal trafficking, which is inhibited by the domi-
for HIV-1 budding. One attractive model is that ubiquiti-
nant negative Vps4 proteins, is required for virus release nation of HIV-1 Gag during viral assembly creates high
through both the PTAP and PPPY motifs. affinity binding sites that recruit Tsg101 to assist in the
final stages of budding. Alternatively, Tsg101 could bind
Tsg101 Depletion and Vps4 Mutations Inhibit Late p6 and recruit a ubiquitinated cellular factor to the site
Stages of Virus Budding of viral assembly. A recent crystallographic analysis of
Thin section electron microscopy was used to charac- the yeast Mms2/Ubc13 complex has confirmed the
terize the defects in viral release from Tsg101-depleted overall similarity of the UEV (Mms2) and E2 (Ubc13) folds
and Vps4-inhibited cells. In both experiments, HIV-1 (VanDemark et al., 2001). In that complex, one face of
budding arrested with “late domain” phenotypes that Mms2 binds Ubc13, creating an active heterodimeric
were very similar to those observed for control PTAP E2 enzyme. A second Mms2 surface then helps bind
mutant viruses (Figure 6A). In each case, isolated imma- protein-conjugated Ub molecules and position their Lys-
ture particles remained connected to the plasma mem- 63 side chains to accept the C-terminal donor ends of
brane via membrane stalks, and budding particles also incoming Ub molecules in the growing poly-Ub chain.
often formed “clusters” of interconnected virions. Al- We have recently determined the three-dimensional
though isolated budding HIV-1 particles were occasion- structure of Tsg101 UEV and find that it also exhibits
ally observed in control cells, these “late domain” mu- an E2-like fold, but that the final two helices in the canon-
tant phenotypes were rarely seen. The dominant ical E2 fold are replaced by the PTAP binding site
negative Vps4 proteins also arrested MLV particle re- (O.W.P. et al., unpublished data). Thus, both Mms2 and
lease at a late stage, with a phenotype that was very Tsg101 UEV couple Ub binding with other protein recog-
similar to that observed for control PPPY mutant vi- nition motifs to facilitate the assembly of multiprotein
ruses (Figure 6B). Thus, HIV-1 and MLV Gag proteins complexes, and this may be a general function of UEV
localized to the plasma membrane of both Tsg101- proteins.
depleted and Vps4-inhibited cells, and appeared to initi-
ate assembly normally. However, the viral particles Tsg101 and the Vps Pathway
failed to complete membrane fission, implying that Tsg101 was initially discovered in a screen for potential
tumor suppressors (Li and Cohen, 1996), and the proteinTsg101 (for HIV-1) and other components of the Vps
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Figure 6. Tsg101 Depletion and Vps4 Mutants Block Virus Budding at a Late Stage
(A) Representative thin section electron micrographs showing the effects on HIV-1 budding of mutating the p6 PTAP sequence (left), depleting
cellular Tsg101 (center), or overexpressing the dominant negative Vps4E228Q protein (right). In each case, virus budding arrested at a late stage,
with immature particles remaining connected to the plasma membrane via membrane stalks or to other budding particles to form “clusters”
of interconnected particles. A subset of the cells transfected with the siRNA and mutant Vps4 constructs exhibited what appeared to be Class
E compartments in the plane of section, and a full description will be published elsewhere. Scale bars are all 100 nm.
(B) Representative thin section electron micrographs showing the effects on MLV budding of mutating the p12 PPPY motif (left) or overexpressing
the dominant negative Vps4E228Q protein (right). These MLV late domain phenotypes are similar to those described above for HIV-1.
appears to perform multiple functions, including down- the Emr laboratory has demonstrated that Vps23 binds
Vps28 and Vps37 to form the “ESCRT-1” complex, whichregulating p53 via the MDM2/p53 pathway (Li et al.,
2001; Ruland et al., 2001). Tsg101 also plays a central selects cargo for incorporation into the lumen of the
MVB (Katzmann et al., 2001). Importantly, both Vps23role in vacuolar protein sorting. The Vps pathway sorts
membrane-bound proteins for eventual degradation in and ESCRT-1 recognize mono- and diubiquitinated sub-
strates, and lumenal MVB targeting in vivo requires sub-the lysosome (vacuole in yeast) (Lemmon and Traub
(2000) and references therein). Two alternative entre´es strate ubiquitination. These observations are in good
accord with previous studies demonstrating functionalinto the Vps pathway are via vesicular trafficking from
the Golgi (e.g., in destroying misfolded membrane pro- roles for Ub conjugation and hydrolysis in targeting pro-
teins into the yeast Vps pathway (Amerik et al., 2000;teins) or via endocytosis from the plasma membrane
(e.g., in downregulating surface receptors). Vesicles car- Dunn and Hicke, 2001; Dupre and Haguenauer-Tsapis,
2001; Galan et al., 2001; Losko et al., 2001; Wang et al.,rying proteins from either source can enter the Vps path-
way by fusing with endosomes. As these endosomes 2001). Although the mammalian Vps pathway is not yet
as well characterized, Tsg101 and Vps23 appear to per-mature, their cargoes are sorted for lysosomal degrada-
tion via the formation of structures called multivesicular form similar roles in vacuolar protein sorting (Babst et
al., 2000; Bishop and Woodman, 2001). At this stage,bodies (MVB). MVB are created when surface patches
on late endosomes bud into the lumen, forming small however, only Tsg101 has been shown to bind to PTAP
(or analogous) motifs, and this may prove to be an impor-(50–100 nm) vesicles. A maturing MVB can contain
tens or even hundreds of these vesicles. The MVB then tant difference between the yeast and human systems.
fuses with the lysosome, releasing the vesicles for deg-
radation in this hydrolytic organelle. Viral Late Domains and Vacuolar Protein Sorting
Our Vps4 dominant negative experiments indicate thatA number of studies indicate that Tsg101 plays a cen-
tral role in the Vps pathway. Deletion of the yeast Tsg101 different retroviruses (HIV-1 and MLV) that use different
late domains (PTAP and PPPY, respectively) neverthe-ortholog, Vps23 (Stp22): (1) gives rise to a class E Vps
phenotype, (2) blocks vacuolar protein sorting from the less both require a functional Vps pathway to bud. This
suggests that the different primary cellular receptors forGolgi, and (3) inhibits surface receptor downregulation
(Babst et al., 2000; Li et al., 1999). Very recent work from the different viral late domains may ultimately recruit
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common factors downstream in the Vps pathway. Cur- particles at the plasma membrane. (2) As noted above,
there is at least circumstantial evidence that two of therent evidence suggests that viruses that bud via PY late
domains interact with members of the Nedd4 family of three proteins thought to function as late domain recep-
tors (Tsg101 and Nedd4) may normally function in MVBproteins (Garnier et al., 1996; Harty et al., 2000; Strack
et al., 2000). A well-established cellular role for Nedd4 cargo selection. Moreover, the cellular receptor for the
YL late domain of EIAV appears to be the AP-50 subunitproteins is to ubiquitinate cell surface receptors and
thereby target them for downregulation via endocytosis of AP-2 (Puffer et al., 1998), a complex that functions
upstream in the pathway in selecting cargo for endocy-and lysosomal degradation (Hicke, 1999; Rotin et al.,
2000). Nedd4 has multiple WW domains that recognize tosis (Owen and Luzio, 2000). (3) Finally, the observation
that the ESCRT-1 complex requires substrate ubiquiti-PY-like motifs on receptors (as well as on viral late do-
mains), and a Hect E3 ubiquitin ligase domain that trans- nation for MVB targeting (Katzmann et al., 2001), cou-
pled with our observation that Tsg101 UEV domain hasfers ubiquitin onto the receptor (Harvey and Kumar,
1999). Importantly, Rsp5 (the yeast ortholog of Nedd4) ubiquitin binding activity, suggests that during the bud-
ding process, Tsg101 may sense the ubiquitination statehas recently been shown to function both in the early
stages of endocytosis and in downstream events in- of a cellular protein or of Gag itself, thereby providing
a rationale for the known requirement for ubiquitin involved in late endosomal trafficking (Dunn and Hicke,
2001; Wang et al., 2001). Thus, it appears that Nedd4 HIV-1 budding (Schubert et al., 2000b; Strack et al.,
2000).and Tsg101 may both help select cargo for incorporation
into multivesicular bodies, perhaps performing comple- In summary, although the different late domain se-
quences of HIV-1 and MLV initially bind different cellularmentary and/or synergistic roles in this process. One
possibility is that Nedd4 conjugates ubiquitin onto target receptors, they may feed into common downstream
steps of the Vps/MVB pathway. Indeed, given the un-proteins and Tsg101 acts as a receptor for the ubiquiti-
nated proteins. usual topology of MVB formation, it will not be surprising
if many other enveloped viruses have evolved mecha-In support of complementary roles for Tsg101 and
Nedd4, many viral coat proteins contain consensus nisms for appropriating the MVB machinery to escape
the cell.binding sites for both Tsg101 (P(T/S)AP) and Nedd4
(PPXY) (Strack et al., 2000). Similarly, there are also
Experimental Procedurescellular proteins with consensus binding sites for both
proteins. One class of proteins that carry both P(T/S)AP
Yeast Two-Hybrid Experimentsand PPXY motifs are surface receptors known to be
Our yeast two-hybrid reagents and techniques have been reviewed
degraded via the Vps pathway (e.g., connexins 43 and (Bartel and Fields, 1997). Briefly, a bait construct expressing HIV-
45) (Berthoud et al., 2000; Strack et al., 2000). A second 1NYU/BR5 p6 (Gag residues 449–500) fused to the C terminus of Gal4
DNA binding domain (residues 1–147) was transformed into yeastclass are proteins that actually appear to function in the
strain PNY200 (MAT trp1-901 leu2-3,112 ura3-52 his3-200 ade2Vps pathway. One such example is hepatocyte growth
gal4 gal80). Prey constructs expressing cDNA from human spleenfactor-regulated tyrosine kinase substrate (Hrs, a homo-
poly(A)	 RNA (Clontech) fused to the C terminus of the Gal4 activa-log of yeast Vps27). Murine cells lacking Hrs exhibit
tion domain (residues 768–881) were transformed into the yeast
abnormal endosomal morphologies, and the protein in- strain BK100 (MATa trp1-901 leu2-3,112 ura3-52 his3-200 gal4
teracts with Nexin 1 (a homolog of yeast Vps5) and gal80 LYS2::GAL-HIS3 GAL2-ADE2 met2::GAL7-lacZ), which incor-
porates the multiple reporter system (James et al., 1996). PNY200thereby helps regulate lysosomal targeting of the EGF
cells (bait) were mated with BK100 cells (prey), and diploid yeastreceptor (Chin et al., 2001; Komada and Kitamura, 2001).
cells were selected in the presence of 3 mM 3-amino-1,2,4-triazoleHowever, not all PTAP and PPPY motifs appear to func-
for the ability to synthesize tryptophan (bait), leucine (prey), histidinetion in pairs, suggesting that other sequence motifs (in
(bait/prey interaction), and adenine (bait/prey interaction). Approxi-
addition to PPXY) can mark proteins for ubiquitination mately 4.2 million bait/prey pairs were tested, and prey encoding
and entry into the Vps pathway and that other recogni- Tsg101 residues 7–390 were isolated twice (Tsg101 NCBI accession
# NM_006292).tion motifs (in addition to PTAP) can target proteins for
Interactions were confirmed by transforming bait and prey con-MVB packaging.
structs into naı¨ve yeast cells and performing liquid culture -galac-
tosidase assays. Cultures were grown overnight in synthetic media
A Potential Role for MVB Machinery (Leu, Trp, 	 glucose) in 96-well plates, normalized for optical
in Virus Budding density, and lysed by addition of 6
 lysis/substrate solution in 6

Z-buffer (60 mM KCl, 6 mM MgSO4, 360 mM Na2HPO4, 240 mMOur studies suggest that HIV-1 Gag may bind Tsg101
NaH2PO4, 6 mg/ml CPRG, 0.12 U/ml lyticase, and 0.075% NP-40).and thereby usurp cellular machinery normally used for
Cultures were incubated for 2 hr at 37C and clarified by centrifuga-MVB formation to facilitate virus budding. The role of
tion, and the optical absorbance of each supernatant was measuredTsg101 in virus budding could be analogous to the pro-
(575 nm). Significant responses were observed for p6 binding to
tein’s normal cellular function of coordinating cargo se- full-length Tsg101 (300-fold over background) and an N-terminal
lection and MVB formation, albeit at a different site—the Tsg101 construct (residues 1–207; 30-fold over background), but
not to a C-terminal Tsg101 construct (residues 207–390).plasma membrane. Several observations are consistent
with this model. (1) As noted by Wills and colleagues
Recombinant Proteins(Patnaik et al., 2000), the topologies of viral budding
DNA encoding Tsg101 residues 1–145 (the UEV domain) was clonedand multivesicular body formation are similar: in both
into pET11d (Novagene), expressed in BL21(DE3) E. coli cells, andprocesses, the membrane invaginates away from, rather
purified by conventional chromatography. Full details of the purifica-
than into, the cytoplasm. Thus, all of the same cyto- tion procedure will be published elsewhere (O.W.P. et al., in prepara-
plasmic machinery used for MVB formation could, in tion). Expression of mutant GST-p6NL4-3 and GST-Ub proteins fol-
lowed the procedures described for wt GST-p6 (Jenkins et al., 2001).principle, work in an analogous fashion to form viral
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Surface Plasmon Resonance 1:3000), anti-GFP-HRP from Clontech (at 1:500), and goat anti-MLV
p30 from John Elder, Scripps Institute, La Jolla (at 1:1000).Surface plasmon resonance measurements were performed at 20C
using a BIACORE 3000 (Biacore AB, Uppsala, Sweden) equipped
with a research-grade CM5 sensor chip. 10 kRU anti-GST Ab was Viral Replication Assays
immobilized on all four flow cells using traditional amine-coupling Infectivity of HIV-1 released into the supernatants from cells trans-
chemistry (Johnsson et al., 1991). Soluble lysates from E. coli ex- fected with R9 constructs was assayed by MAGIC assay in P4 cells
pressing GST-p6 proteins were diluted 10
 in running buffer (20 as described (von Schwedler et al., 1998, and references therein),
mM Na3PO4, 150 mM NaCl, 0.005% P20, and 50 g/mL BSA [pH except that infections were performed at 3 different dilutions in
7.2]) and captured individually on three of the antibody surfaces triplicate in 48-well plates. Blue cells and syncytia were counted 2
at densities of 1–2.5 kRU. 2 kRU recombinant GST protein was days after infection. MLV infectivity was assayed by packaging pCL-
captured on the fourth (reference) antibody surface. lacZ in the M-MLV retroviral vector pCLeco (Naviaux et al., 1996),
Tsg101 UEV in running buffer was injected in triplicate over the transducing NIH3T3 cells, and staining cells for -galactosidase
four flow cells at concentrations of 0, 0.09, 0.27, 0.82, 2.5, 7.4, 22, activity 2 days later, as described (von Schwedler et al., 1998).
67, and 200 M (50 L/min). Data were collected at a rate of 2 Hz
during the 30 s association and dissociation phases. All Tsg 101/p6 Electron Microscopy
interactions reached equilibrium rapidly and dissociated completely Transfected 293T cells were fixed with 2.5% glutaraldehyde/1%
within seconds. To obtain equilibrium dissociation constants, the paraformaldehyde for 30 min and stained as described (von
responses at t  25 s were fit to simple 1:1 interaction binding Schwedler et al., 1998), except that samples were dehydrated in
isotherms (Myszka, 1999). ethanol and embedded in Spurr’s plastic.
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